---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084207"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:44:06.821271+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026

## Summary
- Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.
- Cash $1.1B at Dec 31, 2025; expected runway into Q1 2028.
- Z-rostudirsen in DMD met primary endpoint: dystrophin 5.46% of normal (p<0.0001); BLA submission planned Q2 2026.
- Z-basivarsen in DM1: enrollment completion of registrational cohort expected Q2 2026; topline data Q1 2027.
- Advancing four DMD exon-skipping candidates (exons 53, 45, 44, 55) into IND-enabling studies.

## SEC filing metadata
- accession: 0001193125-26-084207
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/0001193125-26-084207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084207
- JSON: https://secwatch.observer/filing/0001193125-26-084207.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.